New Ulcerative Colitis Drug Shows Promise for Children
A new study indicates that mirikizumab helps children with ulcerative colitis reach remission.
Updated on Oct. 20, 2026 in Children’s Health
Live Poll
Do you trust that new medications approved for adults are sufficiently tested for pediatric use?
The phase 3 SHINE-2 study found that the drug mirikizumab helped children with moderately to severely active ulcerative colitis reach clinical remission. This result offers a potential new treatment pathway for pediatric patients who currently have limited options for managing the condition.
Why it matters
Managing ulcerative colitis in children is challenging due to a scarcity of advanced therapy options designed for pediatric physiology. This research provides evidence on how a targeted treatment may improve symptom control and reduce intestinal inflammation in younger populations.
In a Phase 3 trial of 63 children aged 2 to 17, 50% achieved clinical remission by week 52. The study also recorded a 25.4% endoscopic remission rate at week 12 and a significant decrease in fecal calprotectin levels.
The details
Mirikizumab is an advanced therapy administered via weight-based intravenous induction doses every 4 weeks. Following the induction phase, patients transition to subcutaneous maintenance doses on the same 4-week cycle. The medication aims to modulate inflammatory pathways, as evidenced by a 1,229.9 µg/g decrease in fecal calprotectin—a biomarker of intestinal inflammation—observed by week 12.
Timeline
Week 4: 38.1% of patients achieved symptomatic remission.
Week 12: Clinical remission reached 41.3% of pediatric participants.
Week 52: 50% of participants achieved clinical remission.
Health Landscape
This study extends the SHINE-2 clinical trial program by providing the first pediatric-specific efficacy data for this therapeutic class. It addresses a significant gap in care by testing advanced options for a population historically underserved by adult-focused clinical protocols.
Families managing pediatric ulcerative colitis may want to discuss the availability of advanced therapies with their child's pediatric gastroenterologist. Keep in mind that clinical trial data is population-level, so individual responses to treatment will always vary.
The takeaway
The SHINE-2 trial shows that mirikizumab may be an effective option for children struggling to achieve remission with current ulcerative colitis treatments. Parents should work closely with a gastroenterologist to monitor symptoms and assess whether new clinical data fits their child's care plan.
Further reading
For more on managing long-term digestive conditions, visit our Children’s Health section.
Live Poll
Do you trust that new medications approved for adults are sufficiently tested for pediatric use?
